-transparent.png){kind=logo}
4 healthy volunteers received commercial 20% pure CCK-33 in 4 consecutive doses of 0.5, 1.0, 2.0, 4.0 IDU/kg/h. blood samples were assayed for pancreatic polypeptide (PP) by radioimmunoassay. Plasma PP concentrations increased stepwise from a basal level of 67 +/- 15 pmol/l to a maximum of 198 +/- 46 pmol/l (p less than 0.05). In 4 mongrel dogs with Thomas cannulas, the same doses of 99% pure CCK-33 were successively infused. Plasma PP concentrations rose stepwise with each dose from 44 +/- 7 to 259 +/- 43 pmol/l (p less than 0.02). This rise significantly correlated with pancreatic protein secretion (p less than 0.01). It is concluded that intravenous CCK-33 induces the release of PP in man and in dog, in a dose-dependent manner.
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
June 1989,
Digestive diseases and sciences,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
January 1977,
Lancet (London, England),
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
April 1981,
Hepato-gastroenterology,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
November 1982,
The Journal of pharmacology and experimental therapeutics,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
March 1983,
Zeitschrift fur Gastroenterologie,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
January 1984,
Digestion,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
December 1984,
Regulatory peptides,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
September 1991,
Diabetes research and clinical practice,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
May 1979,
Life sciences,
C Beglinger, and
F Meyer, and
W Häcki, and
K Gyr
July 1978,
Schweizerische medizinische Wochenschrift,
